^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ateganosine (THIO)

    i
    Other names: THIO, 6-thio-dG, 6-thio-2′-Deoxyguanosine
    Associations

    News

    Trials
    Company:
    MAIA Biotech
    Drug class:
    Telomerase inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Maia Biotechnology | Initiation date: Jul 2025 --> Nov 2025
    Trial initiation date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)
    6ms
    THIO-101: THIO Sequenced With Cemiplimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=227, Recruiting, Maia Biotechnology | Trial primary completion date: Dec 2025 --> Jun 2026 | Active, not recruiting --> Recruiting
    Enrollment open • Trial primary completion date • IO biomarker
    |
    Libtayo (cemiplimab-rwlc) • ateganosine (THIO)
    8ms
    A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Maia Biotechnology
    New P3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)
    8ms
    THIO-101: THIO Sequenced with Cemiplimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=227, Active, not recruiting, Maia Biotechnology | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial primary completion date • IO biomarker
    |
    Libtayo (cemiplimab-rwlc) • ateganosine (THIO)
    10ms
    Investigation of the inhibitory effects of the telomere-targeted compounds on glutathione S-transferase P1. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    The dimer form of 6-thio-dG shows strong potential to enhance chemotherapeutic efficacy by effectively inhibiting GSTP1 and overcoming drug resistance. Its superior inhibitory properties make it a valuable candidate for targeted cancer therapies.
    Journal
    |
    GSTP1 (Glutathione S-transferase pi 1)
    |
    ateganosine (THIO)
    1year
    THIO-101: THIO Sequenced with Cemiplimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=182, Active, not recruiting, Maia Biotechnology | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Oct 2026 | Trial primary completion date: Jun 2024 --> Aug 2025
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    Libtayo (cemiplimab-rwlc) • ateganosine (THIO)
    over2years
    Activating an Adaptive Immune Response with a Telomerase-mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. (PubMed, Mol Cancer Ther)
    Importantly, the extracellular HMGB1 (high-mobility group box 1) protein acts as a prototypical endogenous DAMP (Damage Associated Molecular Pattern) in eliciting adaptive immunity by THIO. These results provide a strong rationale for combining telomere-targeted therapy with immunotherapy.
    Journal
    |
    HMGB1 (High Mobility Group Box 1)
    |
    ateganosine (THIO)